Targets › FOLR1
19 programs from 16 companies in 34 trials: 16 Phase 1, 14 Phase 2, 3 Phase 3, 1 Phase 4; Oncology; next expected readout Nov 2026.
Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate and folate analogs into the interior of cells. Has high affinity for folate and folic acid analogs at neutral pH. Exposure to slightly acidic pH after receptor endocytosis triggers a conformation change that strongly reduces its affinity for folates and mediates their release. (UniProt, P15328)
Open in Phaseline: the race on FOLR1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Cedars-Sinai Medical Center | CYTALUX™ (pafolacianine) Folate receptor-targeted fluorescent imaging agent (near-infrared fluorophore conjugate) | FOLR1 | Phase 4 | Gastrointestinal Cancer | Aug 2027 |
| AbbVie | Mirvetuximab Soravtansine Folate receptor alpha binding agent; Tubulin inhibitor | FOLR1, Tubulin | Phase 3 | Ovarian Cancer; High Grade Ovarian Cancer; Recurrent Ovarian Cancer; Advanced High-Grade Epithelial Ovarian Cancer … | Nov 2026 |
| Mayo Clinic | Pafolacianine Sodium Fluorescent imaging agent targeting folate receptor alpha (FOLR1) | FOLR1 | Phase 3 | Childhood Malignant Solid Neoplasm | May 2027 |
| AstraZeneca | AZD5335 Anti-FRα antibody-drug conjugate | FOLR1 | Phase 3 | Epithelial Ovarian Cancer; Fallopian Tube Cancer | Oct 2027 |
| AbbVie | IMGN151 anti-FOLR1 antibody-drug conjugate | FOLR1 | Phase 2 | Gynecologic Cancers; Endometrial Cancer | Feb 2027 |
| CSPC Megalith Biopharmaceutical | SYS6041 anti-FOLR1 antibody-drug conjugate | FOLR1 | Phase 2 | Ovarian Cancer; Advanced Solid Tumors | Mar 2027 |
| John Waters | CYTALUX (pafolacianine) Folate analog ligand conjugated with indole cyanine green-like dye for near-infrared fluor | FOLR1 | Phase 2 | Esophageal Cancer | Dec 2027 |
| Mayo Clinic | Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine Folate receptor alpha-loaded dendritic cell vaccine | FOLR1 | Phase 2 | Advanced Fallopian Tube Carcinoma; Fallopian Tube Carcinosarcoma | Apr 2029 |
| Academic and Community Cancer Research United | Multi-epitope Folate Receptor Alpha Peptide Vaccine Multi-epitope peptide vaccine targeting folate receptor alpha | FOLR1 | Phase 2 | Bilateral Breast Carcinoma | – |
| Beijing Biotech | EB-NK-MF CAR-NK cells Dual-targeting CAR-NK cells engineered to target Mesothelin and Folate Receptor alpha (wit | MSLN, FOLR1, MUC16, TROP2 | Phase 1 | Advanced Solid Tumors; Epithelial Ovarian Cancer | Feb 2027 |
| Epsilogen | MOv18 IgE Anti-folate receptor alpha (FRα) monoclonal antibody of the IgE class | FOLR1 | Phase 1 | Advanced Ovarian Cancer | Mar 2027 |
| Takeda | Mirvetuximab Soravtansine (TAK-853) Folate receptor alpha binding agent; Tubulin inhibitor | FOLR1, Tubulin | Phase 1 | Ovarian Cancer | Mar 2027 |
| Fred Hutchinson Cancer Center | FOLR1 CAR T-cells Anti-FOLR1 chimeric antigen receptor T-cell therapy | FOLR1 | Phase 1 | Recurrent Childhood Acute Myeloid Leukemia | Oct 2027 |
| Changchun GeneScience Pharmaceutical | GenSci140 Folate receptor alpha (FRα) targeting agent for FRα-positive advanced solid tumors | FOLR1 | Phase 1 | Advanced Solid Tumors | Mar 2028 |
| Fred Hutchinson Cancer Center | FH-FOLR1 ST CAR T-cells anti-FOLR1 CAR-T cell therapy | FOLR1 | Phase 1 | Advanced Osteosarcoma | Jan 2029 |
| Phrontline Biopharma | TJ102 CDH6/FRα directed antibody-drug conjugate with dual payloads | CDH6, FOLR1 | Phase 1 | Ovarian Cancer | Sep 2029 |
| Institute of Cancer Research, United Kingdom | Idetrexed Folate receptor-targeted thymidylate synthase inhibitor | TYMS, FOLR1 | Phase 1 | High Grade Serous Ovarian Cancer | Dec 2029 |
| Eisai | Farletuzumab Folate receptor alpha inhibitor | FOLR1 | Phase 1 | Solid Tumor | Aug 2030 |
| Ann & Robert H Lurie Children's Hospital of Chicago | Cytalux Folate analog-fluorophore conjugate targeting folate receptor | FOLR1 | Phase 1 | Osteosarcoma | – |
Ovarian Cancer (6) Epithelial Ovarian Cancer (4) Advanced Solid Tumors (3) Endometrial Cancer (3) Advanced Ovarian Cancer (1) Childhood Malignant Solid Neoplasm (1) Advanced Fallopian Tube Carcinoma (1) Fallopian Tube Carcinosarcoma (1) Recurrent Childhood Acute Myeloid Leukemia (1) Osteosarcoma (1) Esophageal Cancer (1) Solid Tumor (1)
small molecule (8), mixed (8), antibody (2), protein or peptide (1)
Mayo Clinic (2) Fred Hutchinson Cancer Center (2) AbbVie (2) Epsilogen (1) Phrontline Biopharma (1) Beijing Biotech (1) Ann & Robert H Lurie Children's Hospital of Chicago (1) John Waters (1) Eisai (1) Changchun GeneScience Pharmaceutical (1) Academic and Community Cancer Research United (1) Takeda (1) CSPC Megalith Biopharmaceutical (1) AstraZeneca (1) Cedars-Sinai Medical Center (1) Institute of Cancer Research, United Kingdom (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.